{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:58:05Z","timestamp":1788929885847,"version":"build-2803163510"},"reference-count":190,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.pharmthera.2015.05.011","type":"journal-article","created":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T16:18:21Z","timestamp":1431793101000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment"],"prefix":"10.1016","volume":"154","author":[{"given":"Niwanthi W.","family":"Rajapakse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Nanayakkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.05.011_bb0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1071-9164(98)90506-1","article-title":"Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure","volume":"4","author":"Abraham","year":"1998","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bjp.0701836","article-title":"Modulation of angiotensin-converting enzyme by nitric oxide","volume":"124","author":"Ackermann","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0015","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2012.07.036","article-title":"Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction","volume":"60","author":"Akiyama","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0020","doi-asserted-by":"crossref","first-page":"H68","DOI":"10.1152\/ajpheart.2001.280.1.H68","article-title":"Increased inactivation of nitric oxide is involved in coronary endothelial dysfunction in heart failure","volume":"280","author":"Arimura","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cardfail.2010.02.001","article-title":"The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure","volume":"16","author":"Aronson","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0002-9149(98)00872-8","article-title":"Cytokine network in congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy","volume":"83","author":"Aukrust","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0035","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/ndt\/gfq066","article-title":"Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference","volume":"25","author":"Bagshaw","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0040","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ki.2009.503","article-title":"Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease","volume":"77","author":"Barreto","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0045","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ki.2009.503","article-title":"Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease","volume":"77","author":"Barreto","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0050","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","article-title":"Ultrafiltration in decompensated heart failure with cardiorenal syndrome","volume":"367","author":"Bart","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/01.CIR.100.3.292","article-title":"Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production","volume":"100","author":"Bauersachs","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0060","first-page":"119","article-title":"Endothelial dysfunction in heart failure","volume":"60","author":"Bauersachs","year":"2008","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0065","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0006-291X(05)80876-9","article-title":"Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells","volume":"173","author":"Baydoun","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0075","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.V83475","article-title":"Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors","volume":"8","author":"Becker","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0080","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2004-02-0744","article-title":"Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells","volume":"104","author":"Beleslin-Cokic","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0085","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/HYPERTENSIONAHA.111.175810","article-title":"Contribution of central nervous system endothelial nitric oxide synthase to neurohumoral activation in heart failure rats","volume":"58","author":"Biancardi","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0090","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(00)02783-5","article-title":"Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial","volume":"356","author":"Boaz","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0095","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1161\/CIRCULATIONAHA.109.886473","article-title":"Cardiorenal syndrome: new perspectives","volume":"121","author":"Bock","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pharmthera.2007.03.002","article-title":"The L-arginine paradox: Importance of the L-arginine\/asymmetrical dimethylarginine ratio","volume":"114","author":"Bode-Boger","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction","volume":"56","author":"Borlaug","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/HJH.0b013e32835ba77e","article-title":"Angiotensin II-induced hypertension dose-dependently leads to oxidative stress and DNA damage in mouse kidneys and hearts","volume":"31","author":"Brand","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0115","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/01.CIR.0000036600.39600.66","article-title":"Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure","volume":"106","author":"Brede","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2003.08.012","article-title":"Relationship between heart failure treatment and development of worsening renal function among hospitalized patients","volume":"147","author":"Butler","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0125","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/clinchem\/44.8.1809","article-title":"Role of nitric oxide in cardiovascular disease: focus on the endothelium","volume":"44","author":"Cannon","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0130","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurjhf\/hfq038","article-title":"Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial","volume":"12","author":"Castagno","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0135","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1073\/pnas.0409594102","article-title":"Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase","volume":"102","author":"Chalupsky","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0140","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1111\/j.1523-1755.2004.00657.x","article-title":"Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study","volume":"65","author":"Cheung","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0145","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/0735-1097(95)00611-7","article-title":"Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure","volume":"27","author":"Chin-Dusting","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0150","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pharmthera.2007.08.001","article-title":"L-arginine transporters in cardiovascular disease: a novel therapeutic target","volume":"116","author":"Chin-Dusting","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0026-895X(24)26443-9","article-title":"Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters","volume":"57","author":"Closs","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0160","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","article-title":"Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial","volume":"11","author":"Cohen-Solal","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0165","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/01.CIR.0000037105.14195.B6","article-title":"Sympathetic nervous system in heart failure","volume":"106","author":"Cohn","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10741-011-9261-3","article-title":"Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome","volume":"17","author":"Colombo","year":"2012","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0175","doi-asserted-by":"crossref","first-page":"A180","DOI":"10.1016\/S0735-1097(04)90768-1","article-title":"Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utlisation in patients with acute decompensated heart failure","volume":"43","author":"Costanzo","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0180","doi-asserted-by":"crossref","first-page":"R1355","DOI":"10.1152\/ajpregu.00701.2002","article-title":"Role of renal NO production in the regulation of medullary blood flow","volume":"284","author":"Cowley","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0185","first-page":"351291","article-title":"Heart-kidney interaction: epidemiology of cardiorenal syndromes","volume":"2011","author":"Cruz","year":"2010","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0190","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0195","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1046\/j.1523-1755.2001.0590051779.x","article-title":"Bcl-X(L) translocation in renal tubular epithelial cells in vitro protects distal cells from oxidative stress","volume":"59","author":"Cuttle","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","article-title":"Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease","volume":"53","author":"Damman","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0205","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijcard.2012.09.019","article-title":"First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study","volume":"162","author":"Davies","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0210","doi-asserted-by":"crossref","first-page":"882","DOI":"10.4049\/jimmunol.154.2.882","article-title":"Balance between IL-1beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis","volume":"154","author":"Descamps-Latscha","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0215","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJM197305242882102","article-title":"Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction","volume":"288","author":"Dikshit","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0220","first-page":"F650","article-title":"Glomerular ultrafiltration dynamics during increased renal venous pressure","volume":"244","author":"Dilley","year":"1983","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0225","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1161\/CIRCULATIONAHA.107.734921","article-title":"Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease","volume":"117","author":"Dimopoulos","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0230","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00005373-199912000-00002","article-title":"Effect of increased renal venous pressure on renal function","volume":"47","author":"Doty","year":"1999","journal-title":"J Trauma"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0235","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.ajkd.2006.08.015","article-title":"Oxidative stress is progressively enhanced with advancing stages of CKD","volume":"48","author":"Dounousi","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0240","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1067\/mhj.2003.165","article-title":"Hypertonic saline: a novel therapy for advanced heart failure?","volume":"145","author":"Drazner","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0245","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1161\/CIRCULATIONAHA.107.759191","article-title":"Tumor necrosis factor-alpha and mortality in heart failure: a community study","volume":"118","author":"Dunaly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0250","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1161\/CIRCULATIONAHA.107.759191","article-title":"Tumor necrosis factor-alpha and mortality in heart failure: a community study","volume":"118","author":"Dunlay","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0255","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/CIRCULATIONAHA.107.737106","article-title":"Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action","volume":"117","author":"Elkayam","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2006.09.005","article-title":"Use and impact of inotropes and vasodilator therapy in hospitalised patients with severe heart failure","volume":"153","author":"Elkayam","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0265","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archinte.167.11.1130","article-title":"Cardiovascular disease and subsequent kidney disease","volume":"167","author":"Elsayed","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0270","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00424-003-1149-1","article-title":"Nitric oxide in responses of regional kidney perfusion to renal nerve stimulation and renal ischaemia","volume":"447","author":"Eppel","year":"2003","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0275","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0280","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2014.05.007","article-title":"Rationale and Design of the GUIDE-IT Study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure","volume":"2","author":"Felker","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0285","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0290","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1067\/mhj.2001.117606","article-title":"Inotropic therapy for heart failure: an evidence-based approach","volume":"142","author":"Felker","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0295","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/ehi001","article-title":"Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death","volume":"26","author":"Fischer","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0300","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1523-1755.1999.00298.x","article-title":"Coadministration of albumin and furosemide in patients with the nephrotic syndrome","volume":"55","author":"Fliser","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0305","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function","volume":"33","author":"Forstermann","year":"2012","journal-title":"Eur Heart J"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2015.05.011_bb0310","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.3949\/ccjm.73.Suppl_2.S8","article-title":"Acute decompensated heart failure: the cardiorenal syndrome","volume":"73","author":"Francis","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0315","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/01.HYP.0000094557.36656.D0","article-title":"L-arginine reverses p47phox and gp91phox expression induced by high salt in Dahl rats","volume":"42","author":"Fujii","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0320","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3949\/ccjm.73.5.485","article-title":"Addressing the challenges of cardiorenal syndrome","volume":"73","author":"Geisberg","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0330","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0335","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2010.07.246","article-title":"Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial","volume":"16","author":"Giamouzis","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0340","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cardfail.2010.04.006","article-title":"The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study","volume":"16","author":"Gottlieb","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0345","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurjhf\/hft110","article-title":"Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial","volume":"15","author":"Greene","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0350","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1681\/ASN.V13186","article-title":"Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophage-colony-stimulating factor","volume":"13","author":"Greiber","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0355","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/01.RES.74.6.1141","article-title":"Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells","volume":"74","author":"Griendling","year":"1994","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0360","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.cardfail.2014.06.045","article-title":"A stepwise pharmacological care algorithm for cardiorenal syndrome for acute heart failure: insights from DOSE-AHF, CARRESS-HF, and ROSE-AHF","volume":"20","author":"Grodin","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0365","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1046\/j.1523-1755.2001.0590051960.x","article-title":"Elevated plasma F2-isoprostanes in patients on long-term hemodialysis","volume":"59","author":"Handelman","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0370","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000235687","article-title":"Interleukin-6 is a predictor of mortality in stable haemodialysis patients","volume":"30","author":"Hasuike","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0375","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1523-1755.2000.00150.x","article-title":"Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro","volume":"58","author":"Haugen","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0380","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/01.ATV.0000166516.52477.81","article-title":"Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure","volume":"25","author":"Heitzer","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0385","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2369-10-30","article-title":"Overview of the Alberta Kidney Disease Network","volume":"10","author":"Hemmelgarn","year":"2009","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0390","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/S0735-1097(03)00471-6","article-title":"Increased myocardial NADPH oxidase activity in human heart failure","volume":"41","author":"Heymes","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0395","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","article-title":"High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database","volume":"13","author":"Heywood","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0400","first-page":"2198","article-title":"Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans","volume":"80","author":"Higashi","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0405","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0195-668X(02)00526-2","article-title":"Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial","volume":"24","author":"Hillege","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0410","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1053\/j.ajkd.2010.04.012","article-title":"Therapeutic strategies for heart failure in cardiorenal syndromes","volume":"56","author":"House","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0415","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure","volume":"325","author":"Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0420","first-page":"167","article-title":"ABC of heart failure","volume":"320","author":"Jackson","year":"2000","journal-title":"Pathophysiol BMJ"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0425","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1161\/CIRCULATIONAHA.108.837286","article-title":"A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure","volume":"119","author":"Jain","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0430","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/01.RES.53.5.630","article-title":"Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandins","volume":"53","author":"Johnston","year":"1983","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0435","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/hy0202.102700","article-title":"Cationic amino acid transport in the renal medulla and blood pressure regulation","volume":"39","author":"Kakoki","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0440","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.ehj.2003.09.022","article-title":"Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling","volume":"24","author":"Kameda","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jhh.2009.70","article-title":"Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options","volume":"24","author":"Kao","year":"2010","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0450","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.ki.5002482","article-title":"Antioxidative effects of erythropoietin","author":"Katavetin","year":"2007","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0455","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1161\/01.CIR.102.22.2707","article-title":"In vivo and in vitro evidence for impaired arginine transport in human heart failure","volume":"102","author":"Kaye","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0460","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0735-1097(95)00332-0","article-title":"Adverse consequences of high sympathetic nervous activity in the failing human heart","volume":"26","author":"Kaye","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0465","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0735-1097(98)00101-6","article-title":"Increased oxidative stress in patients with congestive heart failure","volume":"31","author":"Keith","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0470","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/S0735-1097(03)00417-0","article-title":"Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality","volume":"41","author":"Kittleson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0475","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000109397","article-title":"Oxidative stress and asymmetric dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients","volume":"28","author":"Kocak","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0480","first-page":"194910","article-title":"Therapeutic options for the management of the cardiorenal syndrome","volume":"2011","author":"Koniari","year":"2010","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0485","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/apha.12215","article-title":"Endothelial cationic amino acid transporter-1 overexpression can prevent oxidative stress and increases in arterial pressure in response to superoxide dismutase inhibition in mice","volume":"210","author":"Konstantinidis","year":"2014","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0490","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0002-9343(98)00365-9","article-title":"Diuretic treatment and diuretic resistance in heart failure","volume":"106","author":"Kramer","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0495","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jacc.2012.08.004","article-title":"Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction","volume":"60","author":"Lam","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0500","doi-asserted-by":"crossref","first-page":"28668","DOI":"10.1074\/jbc.M113.470971","article-title":"Nox4 NADPH oxidase mediates peroxynitrite-dependent uncoupling of endothelial nitric-oxide synthase and fibronectin expression in response to angiotensin II: role of mitochondrial reactive oxygen species","volume":"288","author":"Lee","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0505","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11897-004-0023-6","article-title":"Levosimendan: a calcium-sensitising agent for the treatment of patients with decompensated heart failure","volume":"1","author":"Lehtonen","year":"2004","journal-title":"Curr Heart Fail Rep"},{"issue":"Suppl. B","key":"10.1016\/j.pharmthera.2015.05.011_bb0510","doi-asserted-by":"crossref","first-page":"25B","DOI":"10.1016\/S0828-282X(08)71027-4","article-title":"Cardiorenal syndrome in heart failure: a cardiologist's perspective","volume":"24","author":"Liu","year":"2008","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0515","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9149(92)91194-9","article-title":"Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial)","volume":"70","author":"Ljungman","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0520","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1011428824771","article-title":"The role of interleukin-1 in the failing heart","volume":"6","author":"Long","year":"2001","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0525","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0735-1097(00)00912-8","article-title":"High levels of brain natriuretic peptide and interleukin-6 after optimised treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure","volume":"36","author":"Maeda","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0530","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.cardfail.2008.07.236","article-title":"Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure","volume":"14","author":"Maeder","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0535","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1096\/fj.04-2426fje","article-title":"Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure","volume":"18","author":"Mallat","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0540","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cca.2010.06.019","article-title":"Mechanism of endothelial dysfunction in chronic kidney disease","volume":"411","author":"Malyszko","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0545","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0550","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1161\/01.CIR.94.12.3184","article-title":"Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial","volume":"94","author":"Marcus","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0555","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2011.11.082","article-title":"Endothelial dysfunction, arterial stiffness, and heart failure","volume":"60","author":"Marti","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0560","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0735-1097(98)00209-5","article-title":"Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy","volume":"32","author":"Mathier","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0565","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9343(97)00150-2","article-title":"Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality","volume":"103","author":"McCullough","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0570","doi-asserted-by":"crossref","first-page":"31213","DOI":"10.1074\/jbc.272.50.31213","article-title":"A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the \"arginine paradox\"","volume":"272","author":"McDonald","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0575","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0580","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.semnephrol.2004.04.007","article-title":"Nitric oxide, oxidative stress, and progression of chronic renal failure","volume":"24","author":"Modlinger","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0585","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","author":"Mullens","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0590","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1681\/ASN.V133745","article-title":"Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States","volume":"13","author":"Muntner","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0595","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/bbrc.1997.6428","article-title":"A novel nonenzymatic pathway for the generation of nitric oxide by the reaction of hydrogen peroxide and D- or L-arginine","volume":"233","author":"Nagase","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0600","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jacc.2007.08.072","article-title":"Cardiorenal interactions: insights from the ESCAPE trial","volume":"51","author":"Nohria","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0605","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/heart.89.8.871","article-title":"Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress","volume":"89","author":"Nonaka-Sarukawa","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0610","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s380-002-8317-8","article-title":"Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats","volume":"16","author":"Nozawa","year":"2002","journal-title":"Heart Vessels"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0615","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-99-3-405","article-title":"Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention","volume":"99","author":"Oster","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0620","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00041552-200201000-00014","article-title":"Role of nitric oxide in regulation of the renal medulla in normal and hypertensive kidneys","volume":"11","author":"Pallone","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0625","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ki.1994.117","article-title":"Plasma levels of IL-1beta, TNFalpha and their specific inhibitors in undialysed chronic renal failure, CAPD and hemodialysis patients","volume":"45","author":"Pereira","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0630","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0014-2999(00)00647-6","article-title":"Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro","volume":"406","author":"Persson","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0635","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jacc.2005.04.040","article-title":"Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension","volume":"46","author":"Perticone","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0640","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","article-title":"Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis","volume":"369","author":"Phrommintikul","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0645","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/01.CIR.101.17.2103","article-title":"beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling","volume":"101","author":"Prabhu","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0650","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PCC.0b013e31816c6ed1","article-title":"Worsening renal function in children hospitalized with decompensated heart failure: evidence for a pediatric cardiorenal syndrome?","volume":"9","author":"Price","year":"2008","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0655","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.108.114298","article-title":"Exogenous L-arginine ameliorates angiotensin II-induced hypertension and renal damage in rats","volume":"52","author":"Rajapakse","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0660","doi-asserted-by":"crossref","first-page":"R1669","DOI":"10.1152\/ajpregu.00183.2006","article-title":"ANG II type 2 receptors and neural control of intrarenal blood flow","volume":"291","author":"Rajapakse","year":"2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0665","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00424-004-1320-3","article-title":"Prostaglandins and nitric oxide in regional kidney blood flow responses to renal nerve stimulation","volume":"449","author":"Rajapakse","year":"2004","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0670","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/apha.12344","article-title":"Augmented endothelial-specific L-arginine transport prevents obesity-induced hypertension","volume":"212","author":"Rajapakse","year":"2014","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0675","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1440-1681.2008.05123.x","article-title":"Role of L-arginine in nitric oxide production in health and hypertension","volume":"36","author":"Rajapakse","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0680","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1748-1716.2011.02330.x","article-title":"Role of L-arginine uptake mechanisms in renal blood flow responses to angiotensin II in rats","volume":"203","author":"Rajapakse","year":"2011","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0685","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/MNH.0b013e32835a6ff7","article-title":"Role of cellular L-arginine uptake and nitric oxide production on renal blood flow and arterial pressure regulation","volume":"22","author":"Rajapakse","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0690","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/00005344-200208000-00006","article-title":"Nitric oxide in responses of regional kidney blood flow to vasoactive agents in anesthetized rabbits","volume":"40","author":"Rajapakse","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0695","doi-asserted-by":"crossref","first-page":"R745","DOI":"10.1152\/ajpregu.00477.2004","article-title":"Angiotensin II and nitric oxide in neural control of intrarenal blood flow","volume":"289","author":"Rajapakse","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0700","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.lfs.2007.07.019","article-title":"Nitric oxide and cardiac function","volume":"81","author":"Rastaldo","year":"2007","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0705","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","article-title":"Plasma cytokine parameters and mortality in patients with chronic heart failure","volume":"102","author":"Rauchhaus","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0710","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1067\/mhj.2001.113078","article-title":"Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction","volume":"141","author":"Raymond","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0715","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jacc.2012.01.077","article-title":"Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure","volume":"60","author":"Ronco","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0720","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1046\/j.1523-1755.62.s82.4.x","article-title":"Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney","author":"Ruiz-Ortega","year":"2002","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0725","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/01.RES.70.3.607","article-title":"NG-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. A role for nitric oxide in the central regulation of sympathetic tone?","volume":"70","author":"Sakuma","year":"1992","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0730","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1161\/01.CIR.0000149748.79945.52","article-title":"Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects","volume":"110","author":"Schlaich","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0735","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.ki.5000067","article-title":"Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats","volume":"69","author":"Schwartz","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0740","first-page":"920195","article-title":"The cardiorenal syndrome: a review","volume":"2011","author":"Shah","year":"2010","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0745","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/eurjhf\/hfp053","article-title":"Vascular endothelial function predicts mortality risk in patients with advanced ischaemic chronic heart failure","volume":"11","author":"Shechter","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0750","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7326\/0003-4819-138-11-200306030-00013","article-title":"Pharmacotherapy for heart failure in patients with renal insufficiency","volume":"138","author":"Shlipak","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0755","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/157340310791162659","article-title":"The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease","volume":"6","author":"Sibal","year":"2010","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0760","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11886-012-0258-x","article-title":"The role of renal denervation in the treatment of heart failure","volume":"14","author":"Sobotka","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0765","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/01.CIR.37.6.900","article-title":"Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function","volume":"37","author":"Stampfer","year":"1968","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0770","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1523-1755.2005.00200.x","article-title":"IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia\u2013the good, the bad, and the ugly","volume":"67","author":"Stenvinkel","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0775","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0780","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1523-1755.2000.00236.x","article-title":"Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis","volume":"58","author":"Tepel","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0785","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1523-1755.2004.00969.x","article-title":"Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin","volume":"66","author":"Terawaki","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0790","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cardfail.2014.08.008","article-title":"A combined-biomarker approach to clinical phenotyping renal dysfunction in heart failure","volume":"20","author":"Testani","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0795","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1388-9842(02)00041-7","article-title":"The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis","volume":"4","author":"Thackray","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0800","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0735-1097(95)00589-7","article-title":"Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"27","author":"Torre-Amione","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0805","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1681\/ASN.2004110972","article-title":"Inflammatory markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modelling","volume":"16","author":"Tripepi","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0810","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0735-1097(97)00494-4","article-title":"Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure","volume":"31","author":"Tsutamoto","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0815","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0735-1097(97)00494-4","article-title":"Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure","volume":"31","author":"Tsutamoto","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0820","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0735-1097(99)00594-X","article-title":"Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure","volume":"35","author":"Tsutamoto","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0825","doi-asserted-by":"crossref","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","article-title":"Oxidative stress and heart failure","volume":"301","author":"Tsutsui","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0830","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/S0024-3205(98)00225-2","article-title":"Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure","volume":"62","author":"Usui","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0835","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0840","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1523-1755.2003.00702.x","article-title":"Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency","volume":"63","author":"Vaziri","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0845","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/jcb.22235","article-title":"Reduced L-arginine transport contributes to the pathogenesis of myocardial ischemia-reperfusion injury","volume":"108","author":"Venardos","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0850","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jacc.2010.11.057","volume":"57","author":"Voors","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0855","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/CIRCHEARTFAILURE.109.932558","article-title":"Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials","volume":"4","author":"Wali","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0860","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1161\/01.CIR.0000141829.04031.25","article-title":"Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine","volume":"110","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0865","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/bbrc.1997.9994","article-title":"Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase?","volume":"234","author":"Wascher","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0870","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(08)60952-6","article-title":"All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan","volume":"371","author":"Wen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0875","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1042\/CS20050317","article-title":"Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support","volume":"110","author":"White","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0880","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cardiores.2004.03.008","article-title":"Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent","volume":"63","author":"Widder","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0885","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Writing Committee, M.","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0890","doi-asserted-by":"crossref","first-page":"R1506","DOI":"10.1152\/ajpregu.2000.278.6.R1506","article-title":"Characterization of L-arginine transporters in rat renal inner medullary collecting duct","volume":"278","author":"Wu","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0895","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neuroscience.2004.06.026","article-title":"Effect of erythropoietin on nitric oxide production in the rat hippocampus using in vivo brain microdialysis","volume":"128","author":"Yamamoto","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0900","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0905","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCHEARTFAILURE.108.767483","article-title":"Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Results of the serial infusion of nesiritide (FUSION II) trial","volume":"1","author":"Yancy","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0910","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database","volume":"47","author":"Yancy","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0915","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.amjcard.2006.01.081","article-title":"Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial)","volume":"98","author":"Yancy","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0925","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1681\/ASN.2007040461","article-title":"ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction","volume":"19","author":"Yilmaz","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0920","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10557-007-6066-7","article-title":"Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine","volume":"21","author":"Yilmaz","year":"2007","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0930","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","author":"Young","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0935","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2007.07.067","article-title":"Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry)","volume":"101","author":"Young","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0940","first-page":"F1453","article-title":"Levosimendan protects against experimental endotoxaemic acute renal failure","volume":"290","author":"Zager","year":"2006","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0945","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res"},{"key":"10.1016\/j.pharmthera.2015.05.011_bb0950","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","article-title":"Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study","volume":"358","author":"Zoccali","year":"2001","journal-title":"Lancet"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:41:46Z","timestamp":1748392906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725815001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":190,"alternative-id":["S0163725815001023"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.05.011","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}